Abstract:Background Bladder cancer (BLCA) is a prevalent malignancy affecting the urinary system and is associated with significant morbidity and mortality worldwide. Dysregulation of tumor metabolic pathways is closely linked to the initiation and proliferation of BLCA. Tumor cells exhibit distinct metabolic activities compared to normal cells, and the purine metabolism pathway, responsible for providing essential components for DNA and RNA synthesis, is believed to play a crucial role. However, the precise involvement of Purine Metabolism Genes (PMGs) in the defense mechanism against BLCA remains elusive. Methods The integration of BLCA samples from the TCGA and GEO datasets facilitated the quantitative evaluation of PMGs, offering potential insights into their predictive capabilities. Leveraging the wealth of information encompassing mRNAsi, gene mutations, CNV, TMB, and clinical features within these datasets further enriched the analysis, augmenting its robustness and reliability. Through the utilization of Lasso regression, a prediction model was developed, enabling accurate prognostic assessments within the context of BLCA. Additionally, co-expression analysis shed light on the complex relationship between gene expression patterns and PMGs, unraveling their functional relevance and potential implications in BLCA. Results PMGs exhibited increased expression levels in the high-risk cohort of BLCA patients, even in the absence of other clinical indicators, suggesting their potential as prognostic markers. GSEA revealed enrichment of immunological and tumor-related pathways specifically in the high-risk group. Furthermore, notable differences were observed in immune function and m6a gene expression between the low- and high-risk groups. Several genes, including CLDN6, CES1, SOST, SPRR2A, MYBPH, CGB5, and KRT1, were found to potentially participate in the oncogenic processes underlying BLCA. Additionally, CRTAC1 was identified as potential tumor suppressor genes. Significant discrepancies in immunological function and m6a gene expression were observed between the two risk groups, further highlighting the distinct molecular characteristics associated with different prognostic outcomes. Notably, strong correlations were observed among the prognostic model, CNVs, SNPs, and drug sensitivity profiles. Conclusion PMGs have been implicated in the etiology and progression of bladder cancer (BLCA). Prognostic models corresponding to this malignancy aid in the accurate prediction of patient outcomes. Notably, exploring the potential therapeutic targets within the tumor microenvironment (TME) such as PMGs and immune cell infiltration holds promise for effective BLCA management, albeit necessitating further research. Moreover, the identification of a gene signature associated with purine Metabolism presents a credible and alternative approach for predicting BLCA, signifying a burgeoning avenue for targeted therapeutic investigations in the field of BLCA.

TRIM38 Triggers the Uniquitination and Degradation of Glucose Transporter Type 1 (GLUT1) to Restrict Tumor Progression in Bladder Cancer

Identification of Glycolysis-Associated Long Non-Coding RNA Regulatory Subtypes and Construction of Prognostic Signatures by Transcriptomics for Bladder Cancer

TRIM37 promotes gallbladder cancer proliferation by activating the Wnt/β-catenin pathway via ubiquitination of Axin1

The Oncogenic Role of TFAP2A in Bladder Urothelial Carcinoma Via a Novel Long Noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 Axis.

Silencing Trim59 Inhibits Invasion/migration and Epithelial-to-mesenchymal Transition Via TGF-β/Smad2/3 Signaling Pathway in Bladder Cancer Cells

TRIM38 suppresses migration, invasion, metastasis, and proliferation in non-small cell lung cancer (NSCLC) via regulating the AMPK/NF-κB/NLRP3 pathway

TRIM65 Supports Bladder Urothelial Carcinoma Cell Aggressiveness by Promoting ANXA2 Ubiquitination and Degradation

Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer

TRIM39 Deficiency Inhibits Tumor Progression and Autophagic Flux in Colorectal Cancer Via Suppressing the Activity of Rab7.

TRIM11 Promotes Proliferation and Glycolysis of Breast Cancer Cells Via Targeting AKT/GLUT1 Pathway

Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer

Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy

TUBA1C is a Potential New Prognostic Biomarker and Promotes Bladder Urothelial Carcinoma Progression by Regulating the Cell Cycle

Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer

Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study

Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer

Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients

TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance

TRIM21-mediated Ubiquitylation of TAT Suppresses Liver Metastasis in Gallbladder Cancer

Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation